The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 4, 2011, Pages 825-836

  Feng, Yin Hsun ^a,b   Velazquez Torres, Guermarie ^b,c   Gully, Christopher ^b   Chen, Jian ^b   Lee, Mong Hong ^b,c   Yeung, Sai Ching Jim ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Doxorubicin; Gemcitabine; Insulin; Metformin; Pancreatic cancer; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; GLUCOSE; INSULIN; METFORMIN; ROSIGLITAZONE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; NEOPLASMS; PANCREATIC NEOPLASMS; THIAZOLIDINEDIONES;

MAMMALIA;

EID: 79953685303     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01083.x     Document Type: Article

References (39)

1. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer. 2001; 84: 417-22.
2. Verlato G, Zoppini G, Bonora E, et al Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care. 2003; 26: 1047-51.
3. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2: 48-53.
4. Coughlin SS, Calle EE, Teras LR, et al Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159: 1160-7.
5. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007; 120: 1986-92.
6. Lu XH, Wang L, Li H, et al Establishment of risk model for pancreatic cancer in Chinese Han population. World J Gastroenterol. 2006; 12: 2229-34.
7. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev. 2007; 16: 83-9.
8. Fisher WE. Diabetes: risk factor for the development of pancreatic cancer or manifestation of the disease World J Surg. 2001; 25: 503-8.
9. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005; 294: 2872-8.
10. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995; 273: 1605-9.
11. Permert J, Ihse I, Jorfeldt L, et al Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993; 159: 101-7.
12. Wolf I, Sadetzki S, Catane R, et al Diabetes mellitus and breast cancer. Lancet Oncol. 2005; 6: 103-11.
13. Krone CA, Ely JT. Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther. 2005; 4: 25-31.
14. Fisher WE, Boros LG, Schirmer WJ. Reversal of enhanced pancreatic cancer growth in diabetes by insulin. Surgery. 1995; 118: 453-7.
15. Ding XZ, Fehsenfeld DM, Murphy LO, et al Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000; 21: 310-20.
16. Hudson CC, Liu M, Chiang GG, et al Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002; 22: 7004-14.
17. Galli A, Mello T, Ceni E, et al The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs. 2006; 15: 1039-49.
18. Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. Cancer Ther. 2008; 6: 25-34.
19. Wei S, Yang J, Lee SL, et al PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 2009; 276: 119-24.
20. Efferth T, Sauerbrey A, Steinbach D, et al Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol. 2003; 23: 509-17.
21. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol/Hematol. 2008; 67: 1-7.
22. Hirsch HA, Iliopoulos D, Tsichlis PN, et al Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69: 7507-11.
23. Zakikhani M, Dowling R, Fantus IG, et al Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66: 10269-73.
24. Bowker SL, Majumdar SR, Veugelers P, et al Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-8.
25. Fisher WE, Boros LG, O'Dorisio TM, et al GI hormonal changes in diabetes influence pancreatic cancer growth. J Surg Res. 1995; 58: 754-8.
26. Ekelund S, Liminga G, Bjorkling F, et al Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine. Biochem Pharmacol. 2000; 60: 839-49.
27. UKPDS-Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44: 1249-58.
28. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci. 2008; 65: 3981-99.
29. Jones RG, Plas DR, Kubek S, et al AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005; 18: 283-93.
30. Isakovic A, Harhaji L, Stevanovic D, et al Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007; 64: 1290-302.
31. Wang LW, Li ZS, Zou DW, et al Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol. 2008; 14: 7192-8.
32. Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs. 2005; 14: 557-68.
33. Lyles BE, Akinyeke TO, Moss PE, et al Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle. 2009; 8: 268-77.
34. Dong YW, Wang XP, Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol. 2009; 15: 441-8.
35. Papageorgiou E, Pitulis N, Manoussakis M, et al Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med. 2008; 14: 403-11.
36. Cantini G, Lombardi A, Piscitelli E, et al Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res. 2008; 2008: 904041.
37. Teresi RE, Shaiu CW, Chen CS, et al Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer. 2006; 118: 2390-8.
38. Jiralerspong S, Palla SL, Giordano SH, et al Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27: 3297-302.
39. Nathan DM, Buse JB, Davidson MB, et al Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.